COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn PVP-IPVP-I FLVFLV REGNR2 LY-CoVLY RemdesivirRMD

10/11 Late treatment study
Sili et al., medRxiv, doi:10.1101/2020.10.09.20209775 (Preprint) (not included in the study count)
Factors associated with progression to critical illness in 28 days among COVID-19 patients: results from a tertiary care hospital in Istanbul, Turkey
Source   PDF   Share   Tweet
Analysis of hospitalized patients in Turkey showing HCQ was given to 99.2% of patients and the incidence of critical illness was lower than most studies. Authors note "whether HCQ administration lowered the rates of critical illness development is beyond the scope of this study." There is no comparison with a control group.

Sili et al., 10/11/2020, Turkey, Middle East, preprint, 21 authors.
Details of all 260 studies    Meta analysis
Please send us corrections, updates, or comments.
Submit